Get started

IDXG

Easy - LONG Interpace Biosciences! These guys have 2 COVID products that everyone is waiting for PR's on. They actually just launched a website for their plasma testing kit and we have yet to see an 8-k or PR for it. This is why its so appealing here. The website coviant.com is up. It confirms they had a successful launch and any PR on this would send bring a 100%-200% rally on the COVID pump. It has a target from a reputable firm of $11-$12. Because we are at support and the oscillators look good, this is a long for me. %10 stop loss always applied.
ILong
by GK-Trades
$IDXG On a Clear Breakout with Potential News Down Pipeline$IDXG Latest Insider Purchases, Institutional Ownerships and News: 2016-02-03 Glorikian Harry Director Acquired 127,696 2016-02-03 KEEGAN JOSEPH D Director Acquired 127,696 2016-02-03 STOVER JACK E Interim President and CEO Director Acquired 294,756 2016-02-03 SULLIVAN STEPHEN J Director Acquired 295,656 2017-06-23 SC 13G ARMISTICE CAPITAL, LLC Acquired 965,784 John P. Dugan (Founder): 4,869,878 common shares Other Insiders Approximately: 2,672,149 shares collectively Total Insiders: 7,542,027 shares Institutional Ownership: 30.6% 5.5 mil shares (Increased to 6.5 mil as of June 23rd) Largest Institutional Holder: Heartland Advisors: 2,994,313 Recent News Headlines: 2017-06-28 Interpace Diagnostics Announces National Contract With Aetna 2017-06-26 Interpace Diagnostics Announces Coverage Of Thyroid Test By Premera Blue Cross 2017-06-16 Interpace Diagnostics Announces Pricing Of $13.7 Million Underwritten Public Offering Of Common Stock And Common Warrants 2017-06-06 Interpace Diagnostics Announces Agreement With Einstein Medical Center Of Philadelphia 2017-05-25 Interpace Diagnostics Announces Launch Of Enhancement To Thyroid Testing Services 2017-05-16 Interpace Diagnostics Group's (IDXG) CEO Jack Stover on Q1 2017 Results - Earnings Call Transcript 2017-05-15 Interpace Diagnostics To Host Conference Call And Webcast To Discuss First Quarter 2017 Financial Results On Monday May 15, 2017 2017-05-10 Interpace Diagnostics Presents New Data on PancraGEN® at DDW 2017-04-20 Interpace Diagnostics Eliminates Long Term Secured Debt 2017-04-18 Interpace Diagnostics Announces Coverage Of ThyraMIR With UnitedHealthcare 2017-04-13 Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement 2017-04-04 A Look at Interpace Diagnostics Financials, Drug Pipeline and Market Opportunity 2017-04-03 Interpace Diagnostics Announces European Patent Approval For Underlying Technology Of Its Thyramir Microrna Classifier
ILong
by StockGuild
$IDXG On The Run Again and this time it will be sustainedLet's recap $IDXG CC: 1. New York State and AETNA approvals of ThyraMIR®, microRNA assay 2. Talked about the Debt being restructured 3. No more offerings 4. Reduced operating costs 5. Talks of doing business with their BarreGen model 6. Talks of partnering with another bio he didn't discuss. 7. EPS value of $3.25 vs -($12.04) same quarter last year 8. Sales of $3.122 million. 9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it. 10. 64% of the S/S is SHORT 11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt 12. Revenue increased 39% Also most importantly the Patent Approval!!! $IDXG European Patent Decision data.epo.org ALSO FULL YEAR HIGHLIGHTS READ HERE: ih.advfn.com
ILong
by StockGuild